FDA Partial Hold on Zentalis Azenosertib Clinical Development Program

 FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib

Monotherapy data to be presented in the second half of 2024

Conference call to be held today, June 18, 8:00 am ET

Zentalis will host a live conference call and webcast today at 8:00 a.m. Eastern Time to provide a business update. To access the live conference call by telephone, please register at: https://register.vevent.com/register/BI24249bb9e5714044b9f4057f28565923. Upon registering, each participant will be provided with call details and access codes. The live webcast may be accessed by visiting the event link at: https://edge.media-server.com/mmc/p/y2wz6vv6. The webcast will also be made available on the Company's website at www.zentalis.com under the Investors & Media section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

https://www.globenewswire.com/news-release/2024/06/18/2900260/0/en/Zentalis-Pharmaceuticals-Provides-Update-on-Azenosertib-Clinical-Development-Program.html